Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.
Lazaridis L, Schmidt T, Oster C, Blau T, Pierscianek D, Siveke JT, Bauer S, Schildhaus HU, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M. Lazaridis L, et al. Among authors: blau t. J Cancer Res Clin Oncol. 2023 Jul;149(7):3513-3526. doi: 10.1007/s00432-022-04050-w. Epub 2022 Aug 12. J Cancer Res Clin Oncol. 2023. PMID: 35953681 Free PMC article.
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, Reifenberger G, Kebir S, Dorn F, Blau T, Herrlinger U, Hau P, Ruge MI, Kocher M, Goldbrunner R, Fink GR, Drzezga A, Schmidt M, Langen KJ. Galldiks N, et al. Among authors: blau t. Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95. doi: 10.1007/s00259-014-2959-4. Epub 2014 Nov 20. Eur J Nucl Med Mol Imaging. 2015. PMID: 25411133
Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
Kebir S, Lazaridis L, Weber M, Deuschl C, Stoppek AK, Schmidt T, Mönninghoff C, Blau T, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Stuschke M, Antoch G, Sure U, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Herrmann K, Glas M. Kebir S, et al. Among authors: blau t. Clin Nucl Med. 2019 Jun;44(6):e375-e381. doi: 10.1097/RLU.0000000000002577. Clin Nucl Med. 2019. PMID: 30985412
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T, Oster C, Weller J, Tzaridis T, Pierscianek D, Keyvani K, Kleinschnitz C, Stuschke M, Scheffler B, Deuschl C, Sure U, Herrlinger U, Kebir S, Glas M. Lazaridis L, et al. Among authors: blau t. J Cancer Res Clin Oncol. 2020 Mar;146(3):787-792. doi: 10.1007/s00432-019-03106-8. Epub 2019 Dec 11. J Cancer Res Clin Oncol. 2020. PMID: 31828428
Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey.
Kebir S, Lazaridis L, Wick W, Platten M, Tabatabai G, Combs SE, Schmidt T, Agkatsev S, Blau T, Mäurer I, Kahlert U, Sagerer A, Berberich A, Heider S, Müther M, Bodensohn R, Behling F. Kebir S, et al. Among authors: blau t. Neuro Oncol. 2022 Sep 1;24(9):1609-1611. doi: 10.1093/neuonc/noac114. Neuro Oncol. 2022. PMID: 35639965 Free PMC article. No abstract available.
Prevalence and predictors of neurological manifestations in systemic AL amyloidosis.
Thimm A, Carpinteiro A, Oubari S, Papathanasiou M, Luedike P, Kessler L, Rischpler C, Blau T, Reinhardt HC, Rassaf T, Schmidt H, Kleinschnitz C, Hagenacker T. Thimm A, et al. Among authors: blau t. J Neurol Sci. 2022 Sep 15;440:120341. doi: 10.1016/j.jns.2022.120341. Epub 2022 Jul 18. J Neurol Sci. 2022. PMID: 35872471
59 results